Riding the Femtech Wave: Why Progyny is a Key Stock for Investors to Track


The inventory rate of Progyny (NASDAQ: PGNY), a femtech firm that specializes in fertility and family making rewards methods, has loved important expansion considering the fact that its Oct 2019 listing – demonstrating that the digital women’s health field has developed into a formidable pressure in the wake of the Covid-19 pandemic. 

In spite of new declining prices sparked in no modest aspect by a director promoting $327,285.70 in inventory, Progyny was awarded an average ‘buy’ rating by the 10 brokerages masking the stock. 

Numerous analysts have scrutinized PGNY shares in latest months. Jefferies Monetary Group began coverage on Progyny in a investigate job in December, issuing a ‘buy’ ranking and a $60 goal price tag. Though Citigroup slash their ‘buy’ ranking to a ‘neutral’ ranking for the inventory in November, the analysts also lifted their focus on cost for the inventory from $60 to $64

Nonetheless, Zacks Investments and TheStreet not long ago minimize their rankings for Progyny in 2022, indicating that it could be value marketing up. JPMorgan Chase & Co also lifted their selling price aim for the organization from $65 to $79 and gave the company an ‘overweight’ ranking in an Oct research report. 


As PGNY’s stock general performance historical past exhibits, the inventory has climbed extra than 138% adhering to its Oct 2019 floatation, but buyers are most likely to be involved at how the foremost femtech company has fared amidst the tests current market circumstances of late 2021 – with inflation and new Covid-19 fears paving the way for mass sell-offs. 


The past 6 months demonstrates that the inventory has drifted some 43.26% away from its all-time significant worth of $63.43, which Progyny arrived at in September 2021. 

Yet another contributing aspect to the stock’s latest downturn has been the a little bit beneath-par Q2 revenues in 2021. Though the company’s earnings have been far better than the consensus estimates in excess of the exact period, its inventory has drifted consistently due to the fact Q3 2021. 

Progyny also posted its advice for the entire-12 months 2021 with revenues approximated to access $520 million and EPS set to be all around $.47 at the midpoint of their range. 

“Progyny’s fertility positive aspects alternative incorporates differentiated profit system style and design, personalised concierge-design participant aid products and services and a selective community of fertility professionals,” mentioned Maxim Manturov, head of investment decision information at Independence Finance Europe. “The firm also provides Progyny Rx, a extensive pharmacy gains remedy that offers its customers obtain to the medicines they require in the course of treatment method. In addition, it provides businesses with reimbursement programmes for surrogacy and adoption.”

Progyny noted its Q2 success final month with revenues a little beneath and earnings far better than the consensus estimates. The firm provided its steering for the total-12 months 2021 with revenues estimated to be $520 million and EPS to be all around $.47, at the mid-place of their variety. The combined final results led to a gradual drop of more than 20% in PGNY stock in the to start with 50 % of August. However, the stock has viewed a sharp restoration in excess of the past month or so, led by an elevated optimism for its small business prospects.

The Increase and Rise of Femtech

The quantity of firms in the United States that supply fertility benefits has experienced sustained development in modern many years as the technology powering femtech grows. Benefits options can array from infertility analysis and medicine to in vitro fertilization (IVF) and intrauterine insemination (IUI). Other, far more complete designs deal with egg freezing, the procurement of donor eggs or embryos, and gestational surrogacy. In 1 vital phase for the sector, these kinds of programs have developed to integrate associates of the LGBTQ+ neighborhood, as nicely as single mom and dad. 

The Personnel Gains Study 2020 by the International Foundation of Worker Rewards Options (IFEBP) indicates that 24% of organizations now include IVF remedy, up from just 13% in 2016. The quantity of corporations masking egg harvesting also enhanced from 2% to 10% around the identical period of time. Furthermore, fertility medicine climbed threefold from 8% to 24%. 

Corporations are increasingly keen to adopt fertility advantages as element of their variety, fairness, and inclusion efforts. By giving coverage for therapy and medicine, they can not only develop superior ESG reporting and also guarantee that they can entice and retain far more expertise. 

This heightened desire and recognition of femtech can assistance to accelerate expansion in a fledgling sector which is ripe for adoption. 

Despite the fact that VC desire hasn’t been largely forthcoming in modern several years, the pandemic-pushed increase of electronic transformation and digital wellness has aided sizeable degrees of exposure for women’s health and fitness purposes. 

Progyny may possibly have faced substantial downturns in share selling price in recent months, but the outlook for the femtech industry as a whole need to be regarded as largely optimistic. 

As an early trailblazer in the industry, Progyny will have to be regarded as a business that possesses loads of upside possible. As the market grows, we can count on to see more outperformance for this primary femtech organization.


Resource website link